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INTRODUCTION 
Transdermal drug delivery system is a therapeutic system 
designed to transfer drugs through intact skin for systemic 
treatment. It offers controlled drug release pattern by a 
simple application to the skin's surface, eliminating the 
vagaries influencing the gastrointestinal absorption 
associated with oral administration and providing for more 
efficient drug utilization.It offers various advantages such 
as:avoidance the risk and inconvenience of intravenous 
therapy (noninvasive), avoidance of first pass hepatic 
metabolism (avoiding the deactivation by digestive and 
liver enzymes) thus increasing bioavailability and efficacy 
of drugs, no gastrointestinal degradation (pH, enzymatic 
activity, drug interaction with food, drink and other orally 
administered drugs) andsubstitute for oral administration 
of medication when that route is unsuitable as with 
vomiting and diarrohea1-3. A list of current FDA-approved 
transdermal drug delivery systems is given in Table 14-7. 
Extended therapy avoiding frequent dose 
administration.Fexofenadine,α,α - Dimethyl – 4 - [1-
hydroxy – 4 - [4 - (hydroxydiphenyl-methyl) – 1 -
piperidinyl]butyl]- benzene acetic acid is the active 
carboxylic acid metabolite of terfenadine, and is a non-
sedating selective histamine H1 receptor antagonist. 
Unlike its precursor, fexofenadine lacks the cardiotoxic 
potential, since it does not block the potassium channel 
involved in repolarization of cardiac cells. Fexofenadine is 
effective in the management of allergic rhinitis and chronic 
idiopathic urticaria for which it is a suitable option for 
first-line therapy. It is taken by mouth twice a daily with 
food. The pharmacokinetics of Fexofenadine 
hydrochloride has been studied. It is completely absorbed 
from the gastro-intestinal tract following oral 
administration, but bioavailability is reported to be only 
about 45% due to hepatic first pass metabolism. Most of 
the drug is eliminated in liver as metabolites and only 1% 
of the intact drug is excreted from the kidney. Therefore, 
Fexofenadine hydrochloride might be designed as a 
suitable delivery system with long term effect and bypass 
the liver, such as transdermal delivery system, the delivery 
system may have constant drug delivery rate to the 
circulation system and convenient use for children8-11. 
Table 1:  Currently Approved TDDS 
Year Generic (Brand) Names Indication 
1979 Scopolamine (Transderm Scop®) Motion Sickness 
1984 Clonidine (Catapres TTS®) Hypertension 
1986 Estradiol (Estraderm®) Menopausal Symptoms 
1990 Fentanyl (Duragesic®) Chronic Pain 
1991 Nicotine (Nicoderm®, Habitrol®, Prostep®) Smoking Cessation 
1993 Testosterone (Androderm®) Testosterone Deficiency 
1995 Lidocaine/epinephrine (Iontocaine®) Local Dermal analgesia 
1998 Estradiol/norethindrone (Combipatch®) Menopausal Symptoms 
1999 Lidocaine (Lidoderm®) Post-herpetic neuralgia pain 
2001 Ethinyl estradiol/norelgestromin (OrthoEvra®) Contraception 
2003 Estradiol/levonorgestrel (Climara Pro®) Menopause 
2003 Oxybutynin (Oxytrol®) Overactive bladder 
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Table 1 Continue……….. 
2004 Lidocaine/ultrasound (SonoPrep®) Local Dermal anaesthesia 
2005 Lidocaine/tetracaine (Synera®) Local Dermal Analgesia 
2006 Fentanyl/iontophoresis (Ionsys®) Acute Postoperative pain 
2006 Methylphenidate (Daytrana®) ADHD 
2007 Rivastigmine (Exelon®) Parkinson’s Disease 
2008 Granisetron (Sancuso®) Chemo- induced emesis 
2009 Oxybutynin (Gelnique®) Overactive bladder 
2010 Buprenorphine (Butrans®) Chronic  pain 
 
MATERIALS AND METHODS 
Fexofenadine hydrochloride was obtained as gift sample 
from Ranbaxy Pvt Limited, Toansa. HPMC K-100M, 
HPMC K-4M, ETHYL CELLULOSE was purchased 
fromColorcon Asia Pvt Ltd, Goa, India. All other 
chemicals used were of analytical grade.  
Preparation of matrix patches
 
Polymers of ethyl cellulose and hydroxyl propyl methyl 
cellulose were accurately weighed and dissolved 
individually in 5 ml of ethanol. The drug was then 
dispersed in the polymeric solution and then plasticizer of 
glycerol was added. The solution was stirred to attain 
semisolid like consistency and casted on a glass substrate 
containing ‘o’ ring, the rate of evaporation of solvent from 
polymeric solution was controlled by placed an inverted 
funnel at room temperature for a day. The formed films 
were separated. Formulation of Fexofenadine 
hydrochloride patches was given in Table: 2. 
Table 2: Composition of Transdermal Patches 
 
Preparation of rate controllingmembrane 
The transdermal patches of compositionlisted in Table 1 
were prepared by solvent casting method. The polymer 
(HPMC K100M), (HPMC K4M) and (EC) were dissolved 
in Ethanol at room temperature. Glycerol was used as a 
plasticizer, with continuous mixing at lower rpm initially 
and later at a higher speed. The drug was incorporated with 
continuing agitation and the volume was made up. The 
films were cast onto a suitably designed and fabricated 
glass mould and then dried in oven at 40oC for six hours in 
an oven. The films were removed by using sharp blade by 
inserting along the edges of the film12. The dried films 
were wrapped in butter paper and stored in a closed 
container away from light and in cool place. 
Physical Appearance: 
All the transdermal patches were visually inspected for 
color, clarity, flexibility and smoothness. 
Measurement of Thickness: 
Patch thickness was measured by a dial caliper. The 
average of the five observations was calculated12. Result 
was shown in Table 2. 
Weight Uniformity: 
The dried patches were weighed on digital balance. The 
average of five observations ofeach formulation was 
calculated13. Result was shown in Table 2. 
Folding endurance: 
The folding endurance is expressed as the number of folds 
(no. of times the film is folded at the same place) either to 
break the specimen or to develop visible cracks. This test 
is important to check the ability of sample to withstand 
folding. This also gives an indication of brittleness; less 
folding endurance indicates more brittleness. Folding 
endurance of the film was determined by repeatedly 
folding a small strip of film (2cm x 2cm) at the same place 
till it broke. The number of times, the film could be folded 
at the same place, without breaking gave the valve of 
folding endurance14. Result was shown in Table 3. 
Table 3: Thickness, weight and folding endurance of the patches 
Patch Mean Thickness (mm) 
n=5 
Mean Weight (gm.) (10-3) 
n=5 
Mean Folding Endurance 
n=5 
A 0.413 ± 0.015          0.20±0.020 >100 
B 0.366 ± 0.011 0.203 ± 0.011 >100 
C 0.383 ± 0.015 0.200 ± 0.017 >150 
D 0.393 ± 0.015 0.196 ± 0.025 >100 
E 0.380 ± 0.030 0.153 ± 0.115 >100 
F 0.416 ± 0.015 0.206±0.011 >100 
Sr.No Formulation Code Composition 
(drug: polymer) 
Plasticizer 
(Glycerol) 
Casting solvent 
1 HPMCK100M A 1:1.4 0.1-0.5 ml Ethanol: Dichloromethane 
2 HPMCK100M B 1:2 0.1-0.5 ml Ethanol: Dichloromethane 
3 HPMCK4M C 1:1.4 0.1-0.5 ml Ethanol: Dichloromethane 
4 HPMCK4M D 1:2 0.1-0.5 ml Ethanol: Dichloromethane 
5 ETHYL CELLULOSE E 1:1.4 0.1-0.5 ml Ethanol: Dichloromethane 
6 ETHYL CELLULOSE F 1:2 0.1-0.5 ml Ethanol: Dichloromethane 
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Tensile strength and % Elongation 
The films were taken in rectangular containers using 
proportionate quantity of the solution calculated on the 
basis of area. The films were cut into strips of 1cm width 
and 15cm length. The films were fixed onto the Tensile 
strength apparatus in such a way that the length of film 
between the jaws was initially 10 cm. The trials where the 
breakage occurred at the jaw were invalid and the result 
was repeated on another strip. The Tensile strength was 
calculated by the formula, Tensile strength = Break force 
[1 + change in length] / (width) (breadth) [initial length of 
the film].The percent elongation was determined by noting 
the length just before the break point and substituting the 
formula 
% Elongation = [Final length - Initial length] /Initial length 
* 10015-17. 
In-vitro drug release 
The prepared Fexofenadine hydrochloride patch was 
evaluated for release pattern using commercially available 
semi permeable membrane. The membrane and patch were 
fitted between donor & receptor compartment of self-
fabricated modified Franz diffusion cell. The donor 
compartment was empty & receptor compartment was 
containing 50 ml of phosphate buffer pH 7.4. The samples 
were collected at different time intervals for analyzing the 
drug content in the receptor compartment for release 
pattern of drug and replaced with equal volume of freshly 
prepared phosphate buffer pH 7.4. The drug content was 
analyzed at 259 nm using U.V double beam 
spectrophotometer (Table: 4). From the study best 
formulation was selected for further studies18-20. 
Table 4: In-vitro Release of Fexofenadine hydrochloride Transdermal patches 
 
RESULTS AND DISCUSSION 
The prepared films were smooth, flexible and uniform. 
Total twenty four formulations were formulated using 
HPMCK100M, HPMCK4M and ETHYL CELLULOSE in 
different ratios. The composition of various formulations is 
shown in Table 1. 
Weight variation test was performed by weighing three 
patches and average value was taken as the weight of the 
film. All the formulations exhibited uniform weight with 
low standard deviation values indicating the uniformity of 
the films prepared by solvent casting method. The weight 
of the films varied between 0.20±0.020 to 0.206±0.011 
mg. Thickness of transdermal patches was measured by 
screw gauge. The thickness of the patches varies between 
0.413±0.015 to 0.416±0.015 mm. Low standard deviation 
values in the film thickness measurements ensure 
uniformity of the patches prepared by solvent casting 
technique. The area of the patch was found to be 2.5 cm2.  
The folding endurance of transdermal patches was 
measured manually. The folding endurance of the patches 
is shown in Table 2. Folding endurance test results 
indicated that the patches would not break and would 
maintain their integrity with general skin folding when 
applied. 
The drug content uniformity was determined for all 
formulations by UV spectrophotometer method. The 
results of drug content vary between 18.04±0.047 to 
20.88±0.07 mg as shown in Table 4.7. The results 
indicated that the process employed to prepare patches in 
this study was capable of producing patches with uniform 
drug content and minimal patch variability.  
The results of in vitro drug permeation from different 
formulations are depicted in Table 3. The corresponding 
value of cumulative percentage drug permeated from the 
formulations A, B, C, D, E and F after 24 hrs were 78.2%, 
69%, 61.2%, 59.4%, 70.2% and 65.3%   respectively. 
From the in vitro skin permeation study it was confirmed 
that release of formulations A and E after 24 hrs was found 
to be higher than other formulations (B, C, D and F). The 
kinetic studydata also proves that which follows zero order 
kinetics for controlled release ofdrug to maintain drug 
concentration in better manner 
CONCLUSION 
The drug selected of fexofenadinehydrochloride for 
transdermal therapeutic system of anti-histaminic study 
shown appropriate release in in-vitro studies. This 
confirms that the formulation A and F may control the 
allergic disorder in better manner by achieving drug 
concentration in steady manner for over a day. 
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Formulation code Cumulative percentage of release Time of release 
A 
B 
C 
D 
E 
F 
78.2% 
69.0% 
61.2% 
59.4% 
70.2% 
65.3% 
24hr 
24hr 
24hr 
24hr 
24hr 
24hr 
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